Drug intelligence / Profile preview

MVX-484

Development stage: Unknown
Lead developer: MaveriX Oncology
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

MVX-484 is an orally administered, conditionally activated small-molecule drug conjugate (CA-SMDC) being developed by MaveriX Oncology for the treatment of multiple solid tumors. Utilizing the IMPACT-2X platform technology, MVX-484 is designed to selectively deliver a nucleoside analog cytotoxic payload into the tumor microenvironment by exploiting tumor-associated hydroxylases that are overexpressed in cancer cells and immunosuppressive cells. This targeted delivery results in intratumoral DNA damage and cellular stress, which in turn triggers immunomodulatory and immunostimulatory responses. MVX-484 is currently in Phase 1a development as a daily monotherapy for patients with advanced solid tumors.

Targets

DNAASPH (Aspartyl/asparaginyl beta-hydroxylase)

Beyond the preview

Go deeper on MVX-484.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX-484.

Explore the full profile